I just think 4.00 is a round number with a lot of resistance at that level - - - and - - - there is absolutely no news to give new investors, day traders, or position traders a reason to get involved in the name. The company has at least 5-7 open Ridaforolimus trials going right now, and they had nothing to speak about, whatsoever, at ESMO (other than a hidden abstract which they did nothing with). ASCO was a snoozefest for Ariad. It seems just about every oncology conference, Afinitor (everolimus) has several data presentations to Ridaforolimus' zero.
Hopefully the endometrial trial is actually PR'd and well received. However, because I actually think it is important, it probably will be a non-event. LOL.
